Chimeric Antigen Receptor (CAR) T cell therapy is a highly personalised, targeted and effective therapeutic approach for half-match transplantation and cancer. It involves genetically modifying a pati.....
Chimeric Antigen Receptor (CAR) T cell therapy is a highly personalised, targeted and effective therapeutic approach for half-match transplantation and cancer. It involves genetically modifying a patient's own T cells to recognise and attack cancer cells, reducing damage to healthy cells and prolonging remission periods. Medanta’s state-of-the-art Blood Bank and diagnostic support mean the entire process can be done in-house. CAR T cell therapy has shown remarkable success in treating B-cell acute lymphoblastic leukaemia (B-ALL) and certain types of B-cell non-Hodgkin lymphoma (NHL). Research is ongoing to expand the use of CAR T cell therapy to treat various solid tumours. The therapy can have some side effects such as Cytokine Release Syndrome (CRS) and neurotoxicity.
